AI assistant
HARVARD BIOSCIENCE INC — Director's Dealing 2024
Mar 7, 2024
34975_dirs_2024-03-07_694bc337-430e-4085-997c-f4c7ce1e65b4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HARVARD BIOSCIENCE INC (HBIO)
CIK: 0001123494
Period of Report: 2024-03-05
Reporting Person: Cote Jennifer (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-05 | Common Stock | A | 35800 | $0.00 | Acquired | 142858 | Direct |
| 2024-03-05 | Common Stock | A | 35800 | $0.00 | Acquired | 178658 | Direct |
| 2024-03-06 | Common Stock | F | 9920 | $4.11 | Disposed | 168738 | Direct |
Footnotes
F1: Shares withheld by the Company solely to cover tax obligations upon the vesting of 29,880 restricted stock units ("RSUs").
F2: Represents an award of RSUs that will vest in three equal installments on March 19, 2025, 2026, and 2027.
F3: The number of RSUs represents the target number of RSUs that may be earned based on achievement by the Company of certain performance criteria. The actual number of RSUs awarded may vary between 0% and 150% of the target, depending on the Company's performance. The performance period will end on December 31, 2026.
F4: Includes (a) the awards described in footnotes (2) and (3) above, (b) 17,928 RSUs that will vest in two equal installments on December 29, 2024 and 2025, (c) 11,171 RSUs that will vest on December 29, 2024, (d) 25,862 RSUs with performance based vesting conditions tied to relative total shareholder return and (e) 42,177 shares of common stock beneficially owned by the Reporting Person.